|
Relapsed DLBC treatment options
As a general rule patients who have diffuse large B-cell lymphoma who relapse
after initial treatment will be offered an autologous stem cell transplant as
the preferred treatment. However not every patient is able, or willing to
undergo a stem cell transplant.
There is no single treatment alternative to SCT that is universally accepted
as the "best" option for everyone. Therefore on this page we will try to give
you a list of treatment options that are being used for relapsed DLBC, and other
aggressive forms of NHL. Please be sure to discuss them with your doctor if you
find yourself in this situation.
Use of
myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL
not eligible for standard ASCT: Five-year results
Higher
response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in
nongerminal center b-cell–like than in germinal center b-cell–like phenotype
Phase I study of
bendamustine combined with rituximab in relapsed or refractory aggressive B-cell
non-Hodgkin lymphoma (B-NHL)
An
international phase II trial of single-agent lenalidomide for relapsed or
refractory aggressive B-cell non-Hodgkin’s lymphoma
GEMOX-R regimen is a
highly effective salvage regimen in patients with refractory/relapsing diffuse
large-cell lymphoma: a phase II study.
Randomized
phase III trial of pixantrone compared with other chemotherapeutic agents for
third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma
GROC
(gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less
toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin's
lymphoma (NHL)
Phase II Trial Shows Zevalin(R) Effective Therapy for Relapsed/Refractory
Patients With Diffuse Large B-Cell Lymphoma
90Y
Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory
Diffuse Large B-Cell Non-Hodgkins Lymphoma
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for
patients with relapsed or refractory B-cell lymphoma not candidates for
high-dose therapy
Oral
Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with
Relapsed Aggressive Non-Hodgkin Lymphoma
Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in
Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in
Patients with Relapsed Aggressive Non-Hodgkins Lymphoma: Evidence of Antitumor
Activity from a Phase I Study
A Phase
1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine:
Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell
Lymphoma
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine,
and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic
refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma
Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma:
Outcome with ICE-Based Treatment
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage
therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide,
Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkins
Lymphoma
Ifosfamide,
epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for
refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma
Phase I/II Study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH
Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma
Treatment Response to Single Agent Sphingosomal Vincristine in Patients with
Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin’s Lymphoma
| 
